Academic Journal
A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice
| Title: | A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice |
|---|---|
| Authors: | Errico F., D'Argenio V., Sforazzini F., Iasevoli F., Squillace M., Guerri G., Napolitano F., Angrisano T., Di Maio A., Keller S., Vitucci D., Galbusera A., Chiariotti L., Bertolino A., De Bartolomeis A., Salvatore F., Gozzi A., Usiello A. |
| Contributors: | Errico, F., D'Argenio, V., Sforazzini, F., Iasevoli, F., Squillace, M., Guerri, G., Napolitano, F., Angrisano, T., Di Maio, A., Keller, S., Vitucci, D., Galbusera, A., Chiariotti, L., Bertolino, A., De Bartolomeis, A., Salvatore, F., Gozzi, A., Usiello, A. |
| Publication Year: | 2015 |
| Collection: | Università degli Studi di Bari Aldo Moro: CINECA IRIS |
| Subject Terms: | Adult, Animal, Behavior, Brain, Case-Control Studie, D-Aspartate Oxidase, DNA Methylation, Disease Models, Excitatory Amino Acid Antagonist, Female, Functional Neuroimaging, Human, Magnetic Resonance Imaging, Male, Mice, Knockout, Middle Aged, Motor Activity, Phencyclidine, Prefrontal Cortex, Prepulse Inhibition, Schizophrenia |
| Description: | Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P<0.001) was significantly associated with HAM-D change (n=81, R 2 =0.25, P<0.001). In the fluvoxamine sample, 5-HTTLPR La/Lg, S (P=0.029), FGF2 rs1449683C/T (P=0.013) and EPI (P=0.003) were associated with HAM-D change (n=42, R 2 =0.43, P<0.001). In the milnacipran sample, HTR-1A-1019C/G (P=0.001), ADRA2A-1297C/G (P=0.028) and EPI (P<0.001) were associated with outcome (n=45, R 2 =0.71, P<0.001). EPI in combination with genetic variants could be a useful predictor of treatment outcome and could strengthen the practical use of pharmacogenetic data in clinical practice. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/25689573; info:eu-repo/semantics/altIdentifier/wos/WOS:000367652000005; volume:5; issue:2; firstpage:e512; numberofpages:9; journal:TRANSLATIONAL PSYCHIATRY; https://hdl.handle.net/11586/257047; http://www.nature.com/tp/index.html |
| DOI: | 10.1038/tp.2015.2 |
| Availability: | https://hdl.handle.net/11586/257047 https://doi.org/10.1038/tp.2015.2 http://www.nature.com/tp/index.html |
| Rights: | info:eu-repo/semantics/openAccess ; license:NON PUBBLICO - Accesso privato/ristretto |
| Accession Number: | edsbas.6CD5D327 |
| Database: | BASE |
| DOI: | 10.1038/tp.2015.2 |
|---|